SCHEMBL8158453

SCHEMBL8158453

CSc1n[nH]c(-c2ccc(Cl)cc2)n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCUN1D1 Q96GG9 4/20 0.74
▸ RAB9A P51151 2/20 0.64
▸ POLB P06746 2/20 0.64
▸ KDM4E B2RXH2 2/20 0.64
▸ NPC1 O15118 1/20 0.64
▸ ATM Q13315 1/20 0.64
▸ TYMP P19971 3/20 0.58
▸ ALPL P05186 3/20 0.56
▸ ROCK2 O75116 1/20 0.52
▸ GRK2 P25098 1/20 0.52
▸ NR1H2 P55055 1/20 0.51
▸ NR1H3 Q13133 1/20 0.51
▸ TRPM8 Q7Z2W7 1/20 0.49
▸ MAPT P10636 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ EP300 Q09472 1/20 0.46
▸ MEN1 O00255 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16661193 0.82 DCUN1D1 (0.69) DCUN1D1RAB9APOLBKDM4ENPC1
SCHEMBL16661201 0.80 DCUN1D1 (0.57) DCUN1D1RAB9APOLBKDM4ENPC1
SCHEMBL7635074 0.80 DCUN1D1 (0.71) DCUN1D1RAB9APOLBKDM4ENPC1
SCHEMBL15121080 0.76 ALPL (0.61) DCUN1D1KDM4ETYMPALPLROCK2
SCHEMBL2482181 0.74 HPGD (0.74) DCUN1D1RAB9APOLBKDM4ENPC1
SCHEMBL11187134 0.73 NR1H2 (0.86) DCUN1D1RAB9ANPC1TYMPALPL
SCHEMBL7819474 0.72 ALPL (1.00) DCUN1D1RAB9APOLBKDM4ENPC1
SCHEMBL11511064 0.71 DCUN1D1 (0.66) DCUN1D1RAB9APOLBTYMPALPL
SCHEMBL15119919 0.71 ALPL (0.56) DCUN1D1RAB9AKDM4ETYMPALPL
SCHEMBL8400430 0.71 DCUN1D1 (0.68) DCUN1D1RAB9APOLBKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324058-A1 THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) 2010-12-23 — — US disclosed
US-20100324058-A1 THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) 2010-12-23 — — US disclosed
WO-2009002228-A2 NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) 2008-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324058-A1 THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM F2, PLAT, SERPINC1 DCUN1D1 1780/4885RAB9A 1451/4885POLB 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback